Your browser doesn't support javascript.
loading
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman, Jeff P; Brander, Danielle M; Mato, Anthony R; Ghosh, Nilanjan; Schuster, Stephen J; Kambhampati, Suman; Burke, John M; Lansigan, Frederick; Schreeder, Marshall T; Lunin, Scott D; Zweibach, Alexander; Shtivelband, Mikhail; Travis, Patrick M; Chandler, Jason C; Kolibaba, Kathryn S; Sportelli, Peter; Miskin, Hari P; Weiss, Michael S; Flinn, Ian W.
Affiliation
  • Sharman JP; Willamette Valley Cancer Institute, US Oncology Research, Eugene, OR, USA. Electronic address: jeff.sharman@usoncology.com.
  • Brander DM; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University Health System, Durham, NC, USA.
  • Mato AR; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
  • Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Kambhampati S; Sarah Cannon Cancer Center at Research Medical Center, Kansas City, MO, USA.
  • Burke JM; Rocky Mountain Cancer Centers, US Oncology Research, Aurora, CO, USA.
  • Lansigan F; Hematology/Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
  • Schreeder MT; Clearview Cancer Institute, Huntsville, AL, USA.
  • Lunin SD; Florida Cancer Specialists, Sarasota, FL, USA.
  • Zweibach A; Cancer Care Centers of South Texas, US Oncology Research, New Braunfels, TX, USA.
  • Shtivelband M; Ironwood Cancer and Research Center, Chandler, AZ, USA.
  • Travis PM; Highlands Oncology Group, Fayetteville, AR, USA.
  • Chandler JC; West Cancer Center, Memphis, TN, USA.
  • Kolibaba KS; Compass Oncology, US Oncology Research, Vancouver, WA, USA.
  • Sportelli P; TG Therapeutics, New York, NY, USA.
  • Miskin HP; TG Therapeutics, New York, NY, USA.
  • Weiss MS; TG Therapeutics, New York, NY, USA.
  • Flinn IW; Sarah Cannon Research Institute, Nashville, TN, USA.
Lancet Haematol ; 8(4): e254-e266, 2021 Apr.
Article in En | MEDLINE | ID: mdl-33631112
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Adenine / Leukemia, Lymphocytic, Chronic, B-Cell / Antibodies, Monoclonal Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia Language: En Journal: Lancet Haematol Year: 2021 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Piperidines / Adenine / Leukemia, Lymphocytic, Chronic, B-Cell / Antibodies, Monoclonal Type of study: Clinical_trials / Etiology_studies / Guideline / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte / Asia Language: En Journal: Lancet Haematol Year: 2021 Document type: Article